Drugmaker Johnson & Johnson has halted production of its single-dose COVID-19 vaccine, according to a New York Times report.
The pharmaceutical company last year quietly shut down production at a plant in Leiden, Netherlands, which was the only facility where usable doses of the vaccine were manufactured, catching some of its customers off guard, including developing nations that prefer the single-dose J&J drug over two-dose alternatives, the report states.
Johnson & Johnson has instead been using the plant to work on an experimental and potentially more profitable drug that could protect against an unrelated respiratory virus, according to the report.
The plant is expected to resume manufacturing of the COVID-19 vaccine, but it is unclear when.
J&J did not comment on the plant closure reports, but said in a statement to CBS News “we currently have millions of doses of our COVID-19 vaccine in inventory” and “we continue to fulfill our contractual obligations … [to] the African Union.”